Multiple Daily Injections OR Insulin Pump Therapy: Choosing the Best Option for Your Patient-An Evidence-based Approach

Current Diabetes Reports
Mamta Joshi, Pratik Choudhary

Abstract

Achieving optimal glucose control with minimal hypoglycemia and minimizing the impact of diabetes on quality of life are the aims of management of type 1 diabetes. The main therapeutic options for patients include multiple daily injections (MDI) and continuous subcutaneous insulin therapy (CSII). It is important to differentiate fixed dose MDI with more flexible use, based on carbohydrate counting and structured education programmes, often termed functional insulin therapy (FIT), shown to deliver better outcomes. A significant proportion of patients can achieve optimal glucose control with either therapy, and for those who are unable to achieve desired glucose control with MDI, there is a large body of observational data showing CSII enables them to reduce HbA1c and hypoglycemia, with associated improvements in diabetes-related quality of life. However, in many healthcare systems, guidelines restrict the use of CSII on the basis of cost, with only 20-35 % of patients with type 1 diabetes across Europe using CSII. Although data support improved glucose control and quality of life with CSII, we must recognize that insulin pump therapy is not for everyone and has some downsides such as being attached to a device or issues with can...Continue Reading

References

Jan 28, 1978·British Medical Journal·J C PickupK G Alberti
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Oct 13, 2007·Diabetes Technology & Therapeutics·Laura ScrimgeourH Peter Chase
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Marie L MissoJonathan Shaw
Nov 10, 2011·International Journal of Clinical Practice. Supplement·J Pickup
Feb 22, 2011·Diabetes Care·Tadej BattelinoJan Bolinder
Dec 3, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·D Gunn, P Mansell
Apr 27, 2012·The New England Journal of Medicine·John C Pickup
May 16, 2012·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·C HasselmannF Labarthe
Aug 28, 2012·Journal of Diabetes Science and Technology·Lutz Heinemann, Lars Krinelke
Jun 25, 2013·The New England Journal of Medicine·Richard M BergenstalUNKNOWN ASPIRE In-Home Study Group
Aug 2, 2014·Pediatric Diabetes·B OlsenUNKNOWN Danish Society for Childhood and Adolescent Diabetes
Jan 7, 2015·JAMA : the Journal of the American Medical Association·UNKNOWN Writing Group for the DCCT/EDIC Research GroupJohn M Lachin

❮ Previous
Next ❯

Citations

Aug 10, 2016·Journal of Diabetes Research·A SchaschkowE Maillard
Sep 11, 2016·Materials Science & Engineering. C, Materials for Biological Applications·Jun-Zi WuLi-Min Zhu
Jan 11, 2020·Diabetes/metabolism Research and Reviews·Eugene MerzonAvivit Golan-Cohen
Feb 24, 2017·Diabetes Technology & Therapeutics·Federico BertuzziFabio Garuti
Sep 25, 2019·International Journal of Environmental Research and Public Health·Ewelina Czenczek-LewandowskaArtur Mazur
Dec 2, 2017·Journal of the American Chemical Society·Karthik Nadendla, Simon H Friedman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Related Papers

Diabetes/metabolism Research and Reviews
Bruce W BodePaul C Davidson
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Matthew C LeinungElizabeth Nardacci
© 2021 Meta ULC. All rights reserved